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Abstract
Background: Racial/ethnic minorities have higher incidence and mortality rates of liver cancer, or hepatocellular
carcinoma, than non-Hispanic Whites. As such, the Washington-Baltimore Metropolitan Area Hepatitis B Virus (WBHBV) Demonstration Project, a community-based participatory research (CBPR)-driven academic-community-gov‑
ernment (ACG) partnership, was established in 2019 to address disparities and implement strategies to improve the
HBV screening and vaccination infrastructure for at-risk communities. CBPR is a partnership of community members,
organizational leaders, and academic researchers with a common aim to collectively share and contribute their input
at every phase of the project.
Herein, we describe the process evaluation of the WB-HBV Project and extract themes and insights to benefit future
ACG partnerships and community-engaged research. The process evaluation has been conducted to determine
whether CBPR-driven partnership and programmatic activities have been implemented as intended and have
resulted in building expanded research capacity for future ACG partnership HBV community-level initiatives.
Methods: A WB-HBV Project Task Force was convened and comprised of eight organizations: four community organi‑
zations, three government organizations, and one academic institution. Through a mixed-methods process evalua‑
tion, an online survey and key informant interviews were conducted to provide context for program implementation
barriers and facilitators. Descriptive statistics were conducted, and interviews were recorded, transcribed, and the‑
matically coded.
Results: The survey was completed by 14 of 20 partnership members (70.0%): two academic, eight community, and
four government members. Partnership members showed general agreement across 14 domains: organization and
structure of meetings; trust; decisions; impact; general satisfaction; strategic planning; ACG policy impact; commu‑
nity-based participatory research and government; participation in meetings; assessment of participation; partner‑
ship operations and capacity; communication; challenges/limitations associated with ACG involvement; and benefits
compared to challenges associated with ACG involvement. Qualitative interviews were conducted with 15 of the 20
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members (75.0%): two academic, nine community, and four government members. Four themes emerged: partner‑
ship involvement, project goals and accomplishments, project challenges and barriers, and partnership involvement
in government or policy.
Conclusions: The process evaluation presents insights into developing strategies to enhance partnership function‑
ing and increase the ability of present and future ACG partnerships to improve community health outcomes.
Keywords: Community-based participatory research, Community health partnerships, Community health research,
Health disparities, Health outcomes

Background
Community-based participatory research (CBPR) is a
partnership of community members, organizational
leaders, and academic researchers with a common aim
to collectively share and contribute their knowledge and
expertise to improve the health of community members
[1]. Community members’ active and continued engagement in CBPR is crucial, especially because of challenges
conducting research in underserved communities [2].
CBPR fosters equitable participation of each stakeholder
from the academic, community, and government settings to enable collaborative changes that will improve
the health of community members [3]; CBPR has been
widely used in research and has been shown as an effective method to reduce cancer disparities [4]. However,
challenges in building, engaging, and sustaining CBPR
partnerships often exist [4]. Overcoming these challenges
requires assessing program implementation barriers and
facilitators among the collaborative partnership members
working to improve community health.
Liver cancer, or hepatocellular carcinoma (HCC), is a
leading cause of death worldwide, and approximately
24,000 men and 10,000 women are diagnosed with HCC
each year in the US [5–7]. According to the Centers for
Disease and Prevention (CDC), approximately 18,600
men and 9000 women die from HCC each year [7]. The
risk for HCC increases with chronic hepatitis B virus
(HBV) or hepatitis C virus (HCV) infection. Despite
vaccination and treatment options, respectively, for
HBV and HCV infections, racial/ethnic minorities have
higher incidence and mortality rates than non-Hispanic
Whites [5]. In the Washington-Baltimore Metropolitan
Area (WBMA) from 2009 to 2015, the prevalence rates
of HBV and HCV, respectively, were 6.1 and 3.8% among
Asian-born immigrants and 3.7 and 2.8% for Africanborn immigrants [6]. Since most infected individuals
show little to no symptoms until their liver disease is well
advanced, they are often diagnosed with late-stage cancer that results in low survival rates and high mortality
rates [5–7]. Due to the asymptomatic nature of HCC, it
is crucial to screen and prevent complications from HCC
among foreign-born individuals who have migrated from
countries where hepatitis viruses are endemic.

The Washington-Baltimore Metropolitan Area Hepatitis B Virus (WB-HBV) Demonstration Project is an
integrated, multijurisdictional community coalition that
aims to deliver prompt, responsive, and efficient care
for immigrants from countries where HBV infection is
endemic (e.g., Asia and Africa). The overall objective of
this collaborative academic-community-government
(ACG) partnership is to implement strategies and interventions to improve HBV screening and vaccination
infrastructure for at-risk communities in Washington,
District of Columbia (DC); Maryland; and Virginia. It
covers a cross-state area populated by residents identified by the CDC as being most at-risk for and affected
by this disease. The WB-HBV Project Task Force comprises the National Institute of Diabetes and Digestive
and Kidney Diseases within the National Institutes of
Health, four community organizations (inclusive of primary care physicians, a virologist, and an infectious disease specialist), three local health departments, and the
George Washington University research team. To assess
program implementation barriers and facilitators among
the collaborative partnership members, an external evaluation team was convened to develop and execute a process evaluation plan. The purpose of this article is to (a)
describe the process evaluation of an ACG partnership
created to address HBV health disparities in the WBMA,
and (b) extract themes and insights to benefit future ACG
partnerships and the field of CBPR.

Methods
A WB-HBV Project Task Force was convened and comprised of eight local organizations: four community
organizations, three government organizations, and one
academic institution. Through purposeful sampling,
these organizations were selected based on their historical and current efforts in providing HBV outreach,
education, screening or testing, and linkage to care and
treatment services to at-risk communities, particularly
among the foreign-born population, in the WBMA. This
cross-jurisdictional collaborative partnership was intentionally organized to develop a sustainable model to
allow for HBV health information exchange between providers in the WBMA.
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To conduct process evaluation, an external evaluation
team approached task force members using an online
survey and key informant interviews. This mixed-methods approach using closed and open-ended questions
was implemented to quantitatively and qualitatively provide context for program implementation barriers and
facilitators among members of the WB-HBV Project
Task Force. The external evaluation team consisted of 3
individuals who were not directly involved in the implementation of the WB-HBV Project.
Data collection and measures
Brief partnership interview survey

The quantitative evaluation survey was adapted from
Israel and colleagues [8]. The original survey consisted
of 110 items that assessed 15 domains. Items assessed
included general satisfaction, trust, operations and
capacity, and organization and structure of meetings [8].
To reduce participant burden, the external evaluation
team identified and adopted 69 items from the original survey. A confidential online instrument assessed
the organization and structure of meetings, trust, decisions, impact, general satisfaction, strategic planning,
ACG policy impact, CBPR and government, participation in meetings, assessment of participation, partnership operations and capacity, communication, benefits
of ACG involvement, challenges/limitations associated
with ACG involvement, and benefits compared to challenges associated with ACG involvement. The majority of
the responses were on a 5-point Likert scale: (1) strongly
agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly
disagree. Some responses were on a 4-point Likert scale:
(1) increased, (2) stayed same, (3) decreased, and (4) don’t
know or (1) a lot, (2) moderate amount, (3) not much,
and (4) don’t know.
Key informant interviews

Upon survey completion, participating members of
the WB-HBV Project Task Force were contacted by a
graduate research assistant to schedule their subsequent follow-up key informant interview. The interview
guide consisted of open-ended questions, also derived
from Israel and colleagues [9], on capacity building of
task force members to participate in CBPR partnerships
(Fig. 1) [1, 3].
Interview questions focused primarily on core partnership content areas, which included membership, goals/
accomplishments for the first year, major barriers/challenges for the first year, goals for Project Years 2 and 3,
barriers/challenges for Project Years 2 and 3, organizational impact, government/policy, and partnership. Subtopics of further interest to the evaluation subcommittee
included partnership history (e.g., role in partnership and
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governance; role of community members in the research
process), co-learning experience (e.g., goals and barriers/limitations for Project Years 1, 2, and 3, benefits and
challenges of working in the partnership), and perceptions of the ACG partnership’s effectiveness to address
community needs. All interviews were conducted either
via phone or WebEx by a trained research assistant and
lasted no longer than 1 h.
Data analyses

Survey interview questions were administered online via
Research Electronic Data Capture (REDCap), a secure
web-based application designed to support data capture
for research studies and hosted by the Clinical and Translational Science Institute at Children’s National [10].
The online survey data were downloaded into Statistical
Package for the Social Sciences (SPSS) v.27.0, from which
descriptive statistics (e.g., frequency distribution and
comparison of means) were generated [11].
Audio-recorded interviews were transcribed verbatim
(with members’ permission) for further review and analysis. Each transcript was thematically coded using QSR
International’s NVivo software (version 12 Plus) [12] by at
least two researchers and cross-checked for agreement.
A taxonomy of emergent themes was developed and
shared between all reviewers (DL, AC, MJJ, RH, AS) as an
iterative and collaborative process. Content analysis was
used to examine variations in the data to further refine
the coding scheme [13, 14]. Themes were organized into
overarching domains and compiled with representative
quotations. Discrepancies were resolved through a process of constant comparison until inter-rater reliability
was reached (Kappa coefficient > .80).

Results
16 of 20 partnership members participated in the current study, completing either both the survey and the
interview or at least one of these two components. There
was one participant who completed the survey but not
the interview, and there were two participants who completed the interview but not the survey.
Results from the survey data

The survey was completed by 14 of 20 partnership members (70.0%): two academic, eight community, and four
government members. Collaborative partnership members’ perspectives on partnership-building and research
across the following 14 domains are presented in Table 1:
organization and structure of meetings; trust; decisions;
impact; general satisfaction; strategic planning; ACG policy impact; CBPR and government; participation in meetings; assessment of participation; partnership operations
and capacity; communication; challenges/limitations
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Fig. 1 Interview guide

associated with ACG involvement; and benefits compared to challenges associated with ACG involvement.
Organization and structure of meetings

Members agreed that ACG partnership meetings were
generally useful, well-prepared, and organized; many
felt comfortable voicing their opinions at the meetings.
Although individuals from the academic and government organizations felt that much was accomplished at
these meetings and expressed neutrality regarding the
statement, “I wish we spent more time at partnership
meetings hearing about and discussing ACG projects,”
community members expressed the need for increased
dialogue but were neutral as to whether much was completed during the sessions.

Trust

Participants agreed that the relationships among ACG
members extended to include member organizations
beyond the individuals at the table. They expressed comfort in requesting assistance, introducing new ideas,
speaking frankly, respecting each other’s viewpoints,
and being heard. Academic members reflected a slight
increase in comfort expressing opinions at meetings and
confidence in ACG members collaborating; governmental members experienced increased trust between members over the year prior to the survey.
Decisions

While members expressed satisfaction with ACG decision-making and felt everyone contributed, they were
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Table 1 Collaborative partnership members’ perspectives on partnership-building and research (N = 14)

Total (M, SD) Academic (M, SD) Community (M, SD) Government (M, SD)

Organization and Structure of Meetings
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
1. I find ACG partnership meetings useful.

1.71 (.726)

1.50 (.707)

1.88 (.835)

1.50 (.577)

2. The ACG partnership meetings are well organized.

2.14 (.770)

1.50 (.707)

2.38 (.744)

2.00 (.815)

3. Background materials (agendas, minutes, etc.) needed for
2.29 (.726)
meetings are prepared and distributed well in advance of meetings.

2.50 (.707)

2.25 (.886)

2.25 (.500)

4. I wish we spent more time at partnership meetings hearing
about and discussing ACG projects.

2.79 (.699)

3.00 (.000)

2.50 (.756)

3.25 (.500)

5. We do not accomplish very much at ACG partnership meet‑
ings.

3.57 (.756)

4.00 (1.414)

3.25 (.463)

4.00 (.816)

6. I believe that we adequately address all of the agenda items at
the ACG meetings.

2.29 (.726)

1.50 (.707)

2.50 (.756)

2.25 (.500)

7. When I want to place something on the meeting agenda, I am
comfortable with the process.

2.21 (.802)

1.50 (.707)

2.25 (.886)

2.50 (.577)

8. I would like more of a voice in determining agenda items for
the ACG partnership meetings.

2.86 (.363)

3.00 (.000)

2.75 (.463)

3.00 (.000)

3.50 (.760)

3.50 (.707)

3.25 (.707)

4.00 (.816)

9. One person or group dominates at ACG partnership meetings.

Trust—Part 1
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
10. Relationships among ACG partnership members go beyond
the individuals at the table to include member organizations.

2.21 (.893)

2.50 (2.121)

2.25 (.707)

2.00 (.816)

11. I am comfortable requesting assistance from other partner‑
ship members (when I feel that their input could be of value).

2.07 (.829)

1.50 (.707)

2.38 (.744)

1.75 (.957)

12. I can talk openly and honestly at the ACG partnership meet‑
ings.

2.14 (.770)

1.50 (.707)

2.25 (.886)

2.25 (.500)

13. I am comfortable bringing up new ideas at the ACG partner‑
ship meetings.

2.14 (.770)

1.50 (.707)

2.25 (.886)

2.25 (.500)

14. ACG partnership members respect each other’s point of view
even if they might disagree.

2.29 (.611)

2.00 (.000)

2.38 (.744)

2.25 (.500)

15. My opinion is listened to and considered by other partnership 2.07 (.829)
members.

1.50 (.707)

2.13 (.991)

2.25 (.500)

1.50 (.707)

2.57 (1.134)

2.25 (1.258)

17. Over the past year, the amount of trust between ACG partner‑ 2.29 (1.267)
ship members has:

2.50 (2.121)

2.63 (1.302)

1.50 (.577)

18. In the past year, the ACG partnership members’ capacity to
work well together has:

1.50 (.707)

2.38 (1.188)

2.00 (1.414)

Trust—Part 2
(1) increased, (2) stayed same, (3) decreased, and (4) don’t know
16. In the past year, my willingness to speak and express my
opinions at partnership meetings has:

19. How much trust is there between partners now?
20. In the next year, how much trust do you expect to see
between partners?

2.31 (1.109)

2.14 (1.167)
2.14 (1.351)

2.50 (2.121)

2.13 (1.356)

2.00 (1.414)

2.14 (1.351)

2.50 (2.121)

2.13 (1.356)

2.00 (1.414)

Decisions
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
21. I am satisfied with the overall way in which the ACG partner‑
ship makes decisions.

2.14 (.949)

2.00 (1.414)

2.13 (.991)

2.25 (.957)

22. All partnership members have a voice in decisions made by
the group.

2.07 (.829)

1.50 (.707)

2.13 (.835)

2.25 (.957)

23. It often takes the ACG partnership too long to reach a deci‑
sion.

2.86 (.770)

3.00 (.000)

2.75 (.886)

3.00 (.816)

2.00 (.784)

1.50 (.707)

2.13 (.835)

2.00 (.816)

2.07 (.917)

2.00 (1.414)

2.25 (.886)

1.75 (.957)

Impact
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
24. The partnership of the ACG has been effective in achieving
its goals.
25. The work of the ACG has brought benefits to my community.
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Table 1 (continued)
Total (M, SD) Academic (M, SD) Community (M, SD) Government (M, SD)
26. Participation in the ACG has increased my knowledge and
understanding of the other organizations represented.

2.14 (.770)

2.00 (1.414)

2.25 (.707)

2.00 (.816)

27. Participation in the ACG has increased my knowledge of
health disparities and social determinants of health.

2.00 (.784)

1.50 (.707)

2.00 (.926)

2.25 (.500)

28. Participation in the ACG has increased my organization’s
capacity to conduct communitybased research.

2.14 (.864)

1.50 (.707)

2.25 (.886)

2.25 (.957)

29. ACG-affiliated projects are improving health outcomes for
people in Washington DC metropolitan area.

1.86 (.864)

2.00 (1.414)

1.88 (.835)

1.75 (.957)

General Satisfaction
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
30. I am generally satisfied with the activities and progress of the
ACG during the past year.

2.14 (.770)

2.00 (1.414)

2.25 (.707)

2.00 (.816)

31. I am satisfied with the types of projects that the ACG has
implemented.

2.14 (.864)

2.00 (1.414)

2.38 (.744)

1.75 (.957)

32. I have adequate knowledge of the ACG budget, ACG
resources, and how resources are allocated.

2.71 (1.139)

2.50 (2.121)

2.50 (1.069)

3.25 (.957)

33. I would like to have more input regarding the allocation of
ACG resources.

2.79 (.699)

2.00 (1.414)

2.75 (.463)

3.25 (.500)

34. I am satisfied with the ACG’s efforts to translate research and
evaluation results into information and programs that can improve
health in Washington metropolitan area.

2.50 (.855)

2.00 (1.414)

2.75 (.886)

2.25 (.500)

35. I am satisfied with the ACG partnership’s attention to the
ongoing sustainability of relationships within the partnership.

2.21 (.699)

2.00 (1.414)

2.25 (.707)

2.25 (.500)

36. I am satisfied with the ACG partnership’s attention to building 2.21 (.802)
the capacity of all partners to participate actively in the work of the
partnership.

2.00 (1.414)

2.38 (.744)

2.00 (.816)

Strategic Planning
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
37. Our strategic planning process resulted in the development
of concrete goals and objectives.

2.29 (.726)

2.00 (1.414)

2.25 (.707)

2.50 (.577)

38. Our strategic planning process resulted in the development
of appropriate strategies to accomplish our goals and objectives.

2.29 (.726)

2.00 (1.414)

2.25 (.707)

2.50 (.577)

39. Our strategic planning process has helped to sustain the ACG. 2.29 (.726)

2.00 (1.414)

2.25 (.707)

2.50 (.577)

ACG Policy Impact
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
40. The ACG has been effective in informing policymakers and
key government officials about the ACG and its initiatives.

2.36 (.745)

2.00 (1.414)

2.38 (.744)

2.50 (.577)

41. Involvement with the ACG has provided support for policy
issues my organization feels strongly about.

2.36 (.745)

2.00 (1.414)

2.38 (.744)

2.50 (.577)

42. The ACG has been effective at translating research findings
into policy-relevant documents and educational materials.

2.57 (.852)

2.00 (1.414)

2.63 (.916)

2.75 (.500)

1.00 (.000)

1.63 (.744)

1.50 (.577)

CBPR and Government
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
43. It is important that policymakers and key government officials 1.50 (.650)
are informed about the ACG and its initiatives.
44. Community interests are well represented in ACG activities.

2.14 (.949)

2.00 (1.414)

2.25 (.886)

2.00 (1.155)

45. I served as a co-presenter or presenter representing the ACG
or one of its affiliated projects at a conference, training, or work‑
shop/seminar.

2.64 (1.216)

2.50 (2.121)

2.63 (1.188)

2.75 (1.258)

4.00 (1.414)

1.63 (.744)

2.25 (1.258)

1.50 (.707)

2.38 (.916)

2.50 (.577)

Participation in Meetings
(1) never, (2) 1–3 times, (3) 4–6 times, (4) 7–9 times, and (5) 10–11 times
46. Please indicate approximately how many times over the last
year you have attended ACG partnership meetings

2.14 (1.231)

Assessment of Participation
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
47. I am satisfied with my level of participation in the ACG
partnership.

2.29 (.825)
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Table 1 (continued)
Total (M, SD) Academic (M, SD) Community (M, SD) Government (M, SD)
48. I have taken advantage of opportunities to influence the work 2.57 (.938)
of the ACG partnership.

2.50 (2.121)

2.38 (.916)

3.00 (.000)

49. I devote time outside of partnership meetings to ACG activi‑
ties or projects.

2.50 (2.121)

2.63 (.744)

2.75 (.500)

2.31 (.855)

2.25 (.707)

2.33 (.577)

51. The ACG partnership vision has been translated into concrete, 2.23 (.725)
measurable goals that we aim to achieve.

2.00 (1.414)

2.25 (.707)

2.33 (.577)

52. The ACG partnership effectively represents the diversity of our 2.08 (.760)
communities.

1.50 (.707)

2.25 (.707)

2.00 (1.000)

2.64 (.842)

Partnership Operations and Capacity
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
50. The ACG partnership has a clear vision of what it aspires to
achieve.

2.31 (.855)

53. Community interests are well represented in ACG activities.

2.00 (.816)

2.00 (1.414)

2.25 (.707)

1.33 (.577)

54. The ACG partnership thinks strategically.

2.08 (.760)

1.50 (.707)

2.38 (.744)

1.67 (.577)

55. The ACG partnership is well managed.

2.09 (.862)

2.00 (1.414)

2.25 (.886)

1.67 (.577)

56. The ACG is following its own CBPR principles.

2.15 (.987)

2.50 (2.121)

2.38 (.744)

1.33 (.577)

57. Partnership members take responsibility for getting work
done.

1.85 (.801)

1.50 (.707)

2.13 (.835)

1.33 (.577)

58. In the past year, ACG partnership members’ capacity to work
well together has increased.

1.92 (.954)

2.00 (1.414)

2.13 (.991)

1.33 (.577)

Communication
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
59. Members communicate effectively with each other during
meetings.

1.85 (.801)

1.50 (.707)

2.13 (.835)

1.33 (.577)

60. Partnership members communicate effectively with each
other outside of meetings.

1.92 (.862)

1.50 (.707)

2.13 (.835)

1.67 (1.155)

Benefits of ACG Involvement
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
61. Increasing recognition and respect for my organization in
Washington metropolitan area.

2.25 (.866)

2.00 (1.414)

2.25 (.886)

2.50 (.707)

62. Developing new collaborative relationships between my
organization and other ACG partner organizations.

1.92 (.900)

2.00 (1.414)

2.00 (.926)

1.50 (.707)

63. Working with communities with whom my organization has
previously had little contact.

2.17 (.937)

2.00 (1.414)

1.50 (.707)

2.00 (1.414)

Challenges/Limitations Associated with ACG Involvement
(1) strongly agree, (2) agree, (3) neutral, (4) disagree, and (5) strongly disagree
64. ACG partnership activities do not address my organization’s
goals and interests.

3.31 (1.109)

4.00 (1.414)

3.25 (.886)

3.00 (1.732)

65. Membership in the ACG partnership requires a considerable
time commitment.

3.08 (.862)

3.50 (2.121)

2.75 (.463)

3.67(.577)

66. My (or my organization’s) opinion is not valued within the
ACG partnership.

3.92 (1.038)

5.00 (.000)

3.38 (.916)

4.67 (.577)

4.00 (1.414)

3.13 (.835)

4.00 (1.000)

67. There is too little funding for my organization’s participation in 3.46 (.967)
the ACG partnership.
Benefits Compared to Challenges Associated with ACG Involvement
(1) yes vs. (2) no
68. From your organization’s perspective, do the benefits of
participation in the ACG partnership appear to outweigh the costs
at this point?

1.27 (.467)

1.00 (.000)

1.17 (.408)

1.67 (.577)

69. From your personal perspective, do the benefits of participa‑
tion in the ACG partnership appear to outweigh the costs at this
point?

1.27 (.467)

1.00 (.000)

1.17 (.408)

1.67 (.577)

M Mean, SD Standard Deviation
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neutral about the time the partnership took to reach
decisions.
Impact

Participants felt the partnership was effective regarding its goals, benefits to the community, and improvements in health outcomes in the WBMA. They believed
that participation increased understanding of the other
organizations, knowledge on health disparities and the
social determinants, and capacity for CBPR.
General satisfaction

Members were satisfied with the task force’s activities
and progress, the types of projects implemented, attention to the sustainability of the partnership (as measured across the following three dimensions essential to
sustainability: (1) relationships and commitments from
partnership members, (2) knowledge, capacity, and values of the partnership, and (3) funding, staff, programs,
policy changes, and partnership itself [15]), and capacity
building of partners in the work. Community partners
felt they had somewhat adequate knowledge of the ACG’s
logistics and wanted to provide more input regarding the
allocation of resources, while government partners were
neutral. Community partners were less satisfied with the
ACG’s translation of research and evaluation into information and programs to improve health in the WBMA.
Strategic planning

The sustainability of the ACG partnership depended on
the task force’s strategic planning processes. Participants
agreed that the task force’s strategic planning resulted
in developing (1) concrete goals and objectives, and (2)
appropriate strategies to accomplish them.
ACG policy impact

Participants felt the ACG was effective in informing policymakers about the ACG and its initiatives and in providing support for relevant policy issues. Community and
government members felt that the ACG was less effective
at translating findings into policy-relevant materials.
CBPR and government

Members strongly agreed on the importance of informing key government officials about the partnership and
its initiatives. Members reported that community interests were well represented in ACG activities; however,
opportunities to represent the ACG were somewhat limited for community members.
Participation in meetings

When asked how often participants attended ACG meetings over the last year, partnership members from the
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academic setting reported attending approximately seven
to nine meetings; members from government and community reported attending only one to three meetings.
Assessment of participation

Most participants, especially academic members, indicated satisfaction with their participation level in the
ACG partnership. Community members were more
likely than their academic and government counterparts
to believe that they influenced the work of the ACG
partnership.
Partnership operations and capacity

All members agreed that the ACG partnership thought
strategically, was well-managed, and had a clear vision of
what it aspired to achieve, and that the vision had concrete, measurable goals that members aimed to achieve.
Members also felt that the ACG follows its own CBPR
principles, effectively represents the diversity of the communities, and represents community interests in ACG
activities. However, academic partners, compared to
other members, differed on whether the ACG partnership has a clear vision of what it aspires to achieve and
follows its own CBPR principles. Government members
were more likely to respond favorably to the majority
of the partnership operations and capacity measures.
Across the nine measures within this domain, participants most enthusiastically agreed that ACG partnership
members took responsibility for getting the work done,
and their capacity to work well together had increased in
the past year.
Communication

Participants agreed that ACG members effectively communicated with one another during and outside of partnership meetings; members from the academic and
government settings, however, expressed slightly stronger
agreement than their counterparts from the community.
Benefits of ACG involvement

Participants unanimously agreed that various benefits
were gained from the ACG partnership. Academic members were more likely than their partnership colleagues
to agree that “an increase in recognition and respect for
their institution in the WBMA” occurred, while community and government members were more likely to report
“opportunities to work with communities with whom
the partnering organizations have previously had minimal contact with” and “development of new collaborative
relationships across the partnering organizations” as benefits of their ACG involvement, respectively.
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Challenges/limitations (associated with ACG involvement)

Academic members agreed that the ACG partnership
activities addressed their overall goals and interests,
while community and government members’ feelings on
this topic remained more neutral. Although academic
and government members were more likely to agree that
their opinions (and their organizations’ opinions) were
valued, and substantial funding existed for their respective organizations to participate in the partnership, community partners continued to express neutrality in their
responses on these measures.
Benefits compared to challenges (associated with ACG
involvement)

From organizational and personal perspectives, academic and community members were more likely than
their government counterparts to agree that the benefits
of participating in the ACG partnership outweighed any
challenges encountered to date.
Results from the in‑depth interviews

Qualitative interviews were conducted with 15 of the 20
partnership members (75.0%): two academic, nine community, and four government members. Interviews lasted
from 30 to 45 minutes. As presented in Table 2, four main
themes were identified relating to the ACG partnership:
(1) partnership involvement, (2) project goals and accomplishments, (3) project challenges and barriers, and (4)
partnership’s involvement in government or policy.
Partnership involvement

Role and involvement Community partners were tasked
to screen individuals for HBV surface antibodies, HBV
surface antigens, and HBV core antibodies. Among vaccinated individuals, community partners were also tasked
to confirm which HBV vaccine was administered - either
the 2-dose Heplisev, the 3-dose Engerix B, or the Recombivax HB. Health department partners were expected to
help recruit participants, interpret data collected, and
support the partnership activities. Academic partners
were tasked to complete IRB application and protocol
development as well as manage all community partner
data collection, aggregation, and reporting to the federal
funder. In addition, evaluation teams were expected to
evaluate process and outcome measures.
Benefits of the ACG Partnership Participants described
multiple benefits of the ACG partnership. The primary
benefits described included the synergistic relationship of
the organizations to better address HBV disparities in the
WBMA community and the increased communication
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with other organizations due to partnership. A community organization member said:
So this partnership is so crucial, you know, it needs,
like this table needs four legs, and it needs this four
legs in order for it to work... and so being in this project, it has actually created this big impact. Because,
you know, now we can communicate with the
Department of Health, we can communicate with
the academics, you know, to do publication, so more
people are gonna be aware. And so, so the impact is
big.
Another policy benefit mentioned was the partnership’s
ability to inform policy through information provided to
the academic and government organizations. A community member stated, “It’s important to be able to report
that information and share it in the academic world. And
that those reports and research findings are also shared
with the government so they can make better policy decisions.” Moreover, through the partnership, community
organizations can work with the academic and government organizations to more efficiently and effectively
reach individuals who need help, execute project plans,
and disseminate research findings beyond the academic
and government settings and into the communities. As
two community members pointed out:
Partnerships are to strengthen community relationships and your ability to outreach to the target
population, so that actually gave us a better understanding of actually, what ethnicity needs more help.
Back then we only mainly focused on the Asian, and
African; now we go into the Black community, the
LGBT group, and people [who use] drugs.
It’s benefiting them in the sense that they have somebody and people that are well, knowledgeable about
things about issues that affect the community, they
are benefiting about the fact that we bring to the
community and close to them, you know, services
and resources that they can use in order to continue
to get in control of their own health.
In addition, partnership members affirmed that funding
has helped with resources, especially at the start of the
Coronavirus 2019 (COVID-19) pandemic, when people
were losing jobs and a lot of attention was paid to infectious disease screening and vaccinations. An academic
member said, “Several people got funded and other
groups as well through this grant during the pandemic.
I think it’s really helpful for them. And also, through this
grant, more people are getting screened and vaccinated,
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Table 2 Themes and codes
Theme

Code

Representative Quote

Partnership involvement

Benefits of the ACG partnership

Synergistic Partnership With current project goals, the community partners are now contact‑
ing other communities in need and not just the population previously served:
• “So we’re able to actually tap into a Hispanic group. We also did some LGBT (lesbian, gay, bisexual,
and transgender) groups, as well. And we also got into the people, PWID (people who inject drugs),
so we actually get to the community as well. So with that project that actually helped us expand
even further out.” (community partner)
Three organizations working together for a common goal—betterment of the community:
• “But what I do see is most of these agencies and centers never interact with the academic com‑
munity. And I think this partnership is showing them or at least making them aware of the fact that
the universities also see this as a problem, hepatitis B in the U.S., so I think from that end, it probably
makes them feel good that they’re not the only ones who are saying this is a problem. But the
universities with the big hospitals also see that’s an issue.” (community partner)
• “[…] actually bring a large segment of different areas of service of public health service to the table
is a big accomplishment and a big positive.” (government member)
New Knowledge
Partnership members are gaining new knowledge regarding HBV throughout this partner‑
ship project:
• “I think we’ve learned a lot, or there’s an opportunity to learn a lot in terms of where the gaps are,
what kind of things are needed to improve services for this population.” (academic member)
• “Work with the partnership has increased my awareness of HBV, my understanding of the disease
and of the morbidity, mortality, statistics, and how it impacts especially our Asian immigrant and Afri‑
can immigrant communities, and Hispanics, not only here […] but nationally.” (community partner)
Organizations have expanded their network due to current partnership:
• “So just trying to work closely with them to better understand their networks, and how we can lev‑
erage that, in order for all of us to just be in communication and helping one another and spreading
resources for the patients to reduce liver disease.” (government member)
The partnership is working together, making small incremental steps to reduce disparities for
better community health:
• “So it’s small, incremental things, making positive, incremental changes, that’s what we’ve been
doing. And I think what’s reflected on the community, it may not be overnight, but you can see the
impact over time.” (academic member)

ACG partnership project goals Year 1 Goals
and accomplishments

Goals for ACG partnership
To achieve the goals of ACG partnership and increase communication between
partners:
• “My expectation is to achieve all our goals, and we work towards achieving the goals and hopefully
to exceed as well. […] I was expecting to have better communications.” (community partner)
Quarterly reports
• “Every quarter, we have a quarterly report.” (academic member)
HBV-related Goals
Education and linkage to care:
• “We hope to during the first year… educate more people about the prevalence and have hepatitis
B, and then we hope to connect them also with resources that are in the communities.” (community
partner)
Screening:
• “[…] getting more people to screen […] We need more funding for more screening, more out‑
reach.” (community partner)
Vaccination:
• “They were trying to see if they can increase the number of people who were vaccinated, those
coming from the high endemic areas of hepatitis B, etc., and also increase the vaccination and follow
up for pregnant women and children.” (community partner)
Resources:
• “Resources as, like I said, a lot of our patients don’t have insurance. So they …have to pay out of
pocket to see a doctor. But even you know, most of our patients can’t afford that. And then on top
of that, if they’re positive and their viral load is high, they need medication. And unfortunately, you
know, hepatitis B has no cure. So they’re going to be on medication and monitoring their entire
life. So a lot of people with that extra expense, they’re not going to be compliant with medication
and getting checked every six months. So resources would be providers that see patients just for
free, or medication programs for free. … So location, transportation also falls into that category [of ]
resources. And then the last thing is vaccination because the Asian community has a higher risk of
HBV, we usually recommend that they [and] their family get vaccinated.” (community partner)
Not sure of goals:
• “I don’t know if they didn’t get or not.” (government member)
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Table 2 (continued)
Theme

Code

Representative Quote

Accomplishments so far

HBV-related accomplishments
Exceeded objectives:
• “We exceeded all our deliverables. And even during this pandemic.” (community partner)
Related to COVID-19:
• “Especially with this year, COVID, there’s had to be a lot of adjustments made in terms of how to
effectively reach the target population, and keep them safe.” (community partner)
ACG partnership goals
Building capacity:
• “I think things happen along the continuum. I think that we have made some progress in terms of
building capacity, in terms of engaging the community, but I think the real impact is not there yet.”
(academic member)
Funding and leadership:
• “And that’s funding […] and with the leadership […] has been very successful around funding.”
(community partner)
Presentations:
• “All the presentations […] at least four or five on the first years and completing, finishing all the
other reports quarterly report.” (academic member)
Having everyone at the table:
• “Being able to pull all the partners together at the table is definitely part of the milestone to get
people or organizations involved. So, that part? Yes. The details of the execution, I think is an ongo‑
ing.” (community partner)
• “When they do test positive, there’s about 4 to 5% who test positive for B and about 2 or 3% for C,
and all those individuals are contacted and linked to care services.
And so right now, I think there’s a little bit more effort being put into following up with those
individuals to see whether or not they are actually seeking treatment and on schedule for treatment.”
(community partner)
• “I think that the way in which they were able to bring a mix of academia, direct service providers,
and government to the table, it’s always progress. And this is a major step towards doing much
larger to have an impact on community health. I think that that was a terrific approach. And clearly,
they weren’t doing that. Clearly they weren’t achieving that. But we were all at the table.” (govern‑
ment member)
Others:
• “I think it accomplished that particular goal. And that’s to take a program that’s on paper and
to operationalize it. And to have good reporting systems, have a good relationship between the
partners, which the program has. There’s excellent relationships between the partners. Good data.
So I think it accomplished having the data. And I think more importantly than all of that, well, maybe
as a result of all of that, what I think we all were able to, to actually to actualize was to be considered
probably the best program in the country, among the five or six demonstration programs that were
funded over a year ago with the system’s good data.” (community partner)

Future goals for screening

Sustainability of screening and vaccination:
• “We need to work towards the sustainability of the screening for the hepatitis screening either at
the clinics or private doctor’s offices. And then the vaccination as well.” (community partner)
Involving “champions” in the community:
• “What I hope to tackle next year is to be able to build around us people like champions in the com‑
munity that will be able to multiply what we do in one place to other places.” (community partner)
Birth dose:
• “Most of the clinics, and even the centers that are in this partnership do not work directly with
pregnant women. And I think that’s one of the requests of the grant. So hopefully, they’ll find a way
of incorporating that in the second and third year.” (community partner)
COVID-19:
• “I think it’s also going to depend on this vaccination for COVID-19. And how successful that would
be because then people will then start feeling comfortable to come into the clinics and the centers.
And then the providers also feel comfortable going out to meet people to do the work. So, but I
think they’re doing a really, really good job.” (community partner)
Working with other community organizations, churches:
• “As we all know, the people from the endemic areas are mostly people who are very religious, and
the churches are still open. So if we’re able to access the churches and do trainings in the churches,
we’ll still be able to reach the target population.” (community member)
Educating community about COVID-19:
• “[…] helping to educate the population about COVID.” (academic member)
Screening, educating, vaccinating:
• “Just screen as many patients as we can, provide education, more vaccines to prevent HBV and get
people treated and linked if they test positive.” (community member)
Health Fair:
• “So we are planning a health fair […] So we have more people vaccinate, and we have more people
come out for the health fair, and it’s always a good way for us to boost up the number.” (community
member)
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Table 2 (continued)
Theme

Code

Representative Quote

Future goals for ACG partner‑
ship and recommendations

Goals for systems
Continuity of care:
• “The first area has to do with how well governmental partners such as the health departments work
together with the community partners, so that there’s much more of an ability to have continuity,
especially for those persons who are HBV positive, helping to make sure that the reporting systems
between community and governmental entities are strengthened. Also, so that’s much more of your
health information exchange goal that’s in the proposal. So I’m hoping that in Year Two and Year
Three that gets attention.” (community member)
EMR, standardizing screening:
• “There is a goal related to electronic medical records so that HBV becomes a part of anyone’s care
coming in through the door. […] So standardizing HBV screening and care as part of patient care is
important.” (community member)
Raising awareness about HBV among minorities:
• “Raising awareness, letting people know that there’s a lot of communities like Asians and Africans,
where HBV is prevalent, and it’s not just because of STDs, but it’s because of where these are from.
So that people are aware that there are big groups of hepatitis B positive patients that need to be
addressed. So that we aren’t spreading.” (community member)
Dissemination:
• “There could be a summit or some sort of conference. There could be a creation of some sort of
case consultation, for example, around perinatal hepatitis B. There could be engagement with medi‑
cal providers around hepatitis B as an issue. There could be a coordinated activity where maybe one
day is selected to actually promote and provide, for example, hepatitis B-related services. Whether it’s
general community education, or otherwise, an emphasis on testing, for example, but that it would
happen in multiple sites at the same time and promoted by all as one group one body.” (government
member)
Refine Project in the context of COVID-19 pandemic:
• “We need to now begin to think in the context of implementing this program. In the context
of COVID… COVID will still be with us next year. So the issue of safety precautions and ensuring
implementation of community testing and community events in a safe manner will still be very
relevant, so that context needs to be built into the program. […] Nobody was thinking of COVID
before. Implementing this kind of program, this academic, community, and government partnership
project to reduce hepatitis B virus, needs to be built with a strong context around COVID-19 in mind.”
(government member)
Other objectives
Birth dose:
• “Another thing came up more recently is the birth dose, Hep B birth dose […], engagement, and
tracking and that kind of things. And mostly previously, it’s more on immigrants - African and Asian.
So we need to figure out how to engage with pregnant women and get into vaccinating when they
have a baby within a day. So that would be one thing we hope to accomplish with documented
changes and interventions and see we can get something done.” (academic member)
Unsure
Unsure about goals for Years 2 and 3:
• “That I’m not sure.” (community member)
Need for clear communication and attendance in meetings to better understand project
goals:
• “We weren’t included in more of those meetings that may help us better understand other partners
who are involved in other parties that we can leverage or who may be interested in working with us.”
(government member)
• “If we were to attend more meetings, I definitely think that could be advantageous to us.” (govern‑
ment member)
• “And so what I really do hope for the project is that they continue to work together as a partnership.
And really solidify that partnership and a couple of areas that are in the grant proposal that still
needs strengthening.” (community member)
• “Hopefully, we can have more engagement, communication, a meeting. So currently, for example,
just some of us meeting more regularly. Hopefully will be more frequent. But this could be a down‑
side to that. And just more time will be involved.” (academic member)
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Table 2 (continued)
Theme

Code

Representative Quote

ACG partnership project chal‑
lenges and barriers

Overall challenges so far

ACG partnership
Time to communicate:
• “It’s a major barrier and challenges with the partnership. It’s coordinating the time to communicate.
Coordinating and scheduling time to coordinate. […] And we were planning to do three meetings
for Year One. But the third meeting, we’re not able to do because of COVID, and that’s our biggest
challenge.” (community member)
Addressing birth dose:
• “One of the challenges is that one of the goals was to focus on birth dose and trying to identify the
best way to look at that, measure that, examine that. So that’s been a challenge. And so I think the
team has been really working hard trying to identify ways they could address birth dose.” (academic
member)
Being clear on goals and outcomes:
• “One challenge, again, is that I think the whole partnership needs to be clear on what the overall
goals are, and what the outcomes are. So that has not been as transparent as I think I would like.”
(academic member)
HBV
Reaching out to target population:
• “The barriers during the first year I think it was basically to get the word around and then get the
people we found positive to get treatment.” (community member)
Lack of ability to reach out to the community and other racial/ethnic minorities:
• “What we lack is the ability to reach out to the community and other ethnicity organizations.” (com‑
munity member)
Mistrust from community:
• “We had to learn ways to adapt. […] What are you here for, there’s no such thing as free. So that’s
always a barrier, is there cost or the hidden costs?” (community member)
Working with three different communities:
• “We have to be cognizant that each of these has their own dynamic within their community, how
they are seeing, who they connect with, what, how they can work with their policymakers, so on
and so forth, how they work within their medical and health, infrastructure within that community.
I think that’s the part that may be lacking a bit. How do we build up each of our partners within the
networks that they live within?” (community member)

Anticipated future challenges
and barriers and recommenda‑
tions to overcome challenges

Related to HBV
Continued challenges due to COVID-19:
• “The challenges so far remain just the COVID issue. […] And we hoped that it can get in control as
soon as possible so we can go back to those large physical settings that we use to do in order to
educate more people.” (community member)
Related to ACG Partnership
Lack of funding:
• “I think funding, funding from CDC is a major barrier and that needs to be brought to their atten‑
tion.” (community member)
• “Funding is usually a major barrier.” (community member)
Transparency of partnership goals and outcomes:
• “One challenge, again, is that I think the whole partnership needs to be clear on what the overall
goals are, and what the outcomes are. So that has not been as transparent as I think I would like.”
(academic member)
Equitable relationship with partners:
• “I would make sure that the community partner, their relationship is equitable, that it is not so
academic driven.” (academic member)
Challenges in Health Information Exchange:
• “Building up that capacity around EMR systems, I think that’s going to go on for a while. And hope‑
fully, we can get that together so that it becomes standardized practice.” (community member)
Challenges in evaluation and sustainability of the program:
• “So I do think that heading toward the middle of Year Two and Year Three, there has to be a conver‑
sation about the partnership, whether it’s a partnership that’s going to disappear, or whether there
are monies that hold the partnership together, or even without money as what other things do they
have in common that really motivates them to stay together as a partnership. That’s going to be a
challenge.” (community member)
Completion of the project:
• “So we have one year, a few months under our belt. And I think one challenge …, we have to be
more open to different audiences, different settings, and engage with different populations. So that
could be a challenge as well. So that’s why we hope for completion but the challenge for us is the
pandemic.” (academic member)
Time commitment:
• “In the perspective of managing the national task force and hepatitis B, we have monthly meetings.
And I think one of the biggest challenges of having standing meetings is the time to time commit‑
ment, especially, if you’re asking individuals who are not doing this as a full-time job, to carve out
some time during the workweek to meet, I think that could be potentially one of the biggest chal‑
lenges if this is not their full-time job.” (community member)
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Table 2 (continued)
Theme

Code

Representative Quote

ACG partnership involvement
in government or policy

Current involvement in govern‑
ment or policy

Current involvement in government or policy:
• “Your local department of health is sort of like your policy agency, in many respects, at least for local
policy. So the fact that we’ve been at the table would sort of lead to that.” (government member)
Not currently involved in government or policy:
• “We are so busy doing the groundwork, doing the grassroots work. So we never have an opportu‑
nity to talk to the government or the academic.” (community member)
• “I don’t think this project is involved in any of the policy.” (community member)
Uncertain:
• “I believe so. So I myself didn’t really pay a lot of attention on the policy level, because [I am] occu‑
pied with tasks.” (community member)
• “I’m not sure about this answer, but I will, I would think yes, but I’m not sure about this answer.”
(community member)
• “To the best of my knowledge, I have no idea. I really don’t.” (community member)

Future recommendations for
involvement in government or
policy

Increase Community Testing/Screening, Vaccination, and Education
Increase testing available to minority population:
• “Hepatitis B vaccination should be made available free for people who don’t have insurance, espe‑
cially for the adult population.” (community partner)
Immigrant Health Policy
Dissemination of findings to legislatures interested in immigrant health:
• “In the Chinese community, the medical community, there are professionals trying to advocate for
the community for hepatitis B, hepatitis B resource. So I know, at least like 10 years ago, a physician,
[…] he was able to really go to the Capitol Hill and fascinate the Congress. So we have an event like
that. And he was very successful.” (community partner)

and linked to care. So that’s, I think it’s substantial health
benefits as well.”
Project goals and accomplishments

Year 1 goals Several goals were mentioned by partnership members, including goals within the ACG partnership and HBV-specific goals. Within the partnership,
members wanted to “have more communications,” build
capacity, and complete all contractual deliverables. In
terms of building capacity, a community member highlighted the importance of having multiple perspectives in
the planning and delivery of services:
Yeah, so my understanding when the partnership
meetings were set up, it was to engage different
stakeholders in the decision-making of being able to
outreach, educate, screen link patients to care services relating to hepatitis B, and possibly C, depending on the stakeholders and, you know, where their
focus and interest is. So, the stakeholders should
have included community-based organizations, the
academic institutes, and the government agency, so
that there are multifaceted perspectives in the decision-making of that cascade of care.
Regarding goals related to HBV, participants indicated
increasing education, screening, vaccination, outreach,
resources, and linkage to care. Community members
conveyed that providing education and resources and

linking patients to care will help lower infections and
“bring awareness to the disparities and the different communities that have HBV, and ultimately … a little bit
more resources to help these patients.”
Although some members knew the screening goals,
others were not too certain what the task force’s project goals were. One commented, “So I’m not really sure
what the overall goals were and if they met them or not.”
Recommendations included further strengthening the
communication between core members of the ACG leadership team (specifically on what the future goals for the
partnership should be) and increasing overall engagement and attendance at the ACG meetings.
Accomplishments to‑date Members confirmed that the
ACG partnership exceeded their goals; some expressed
their appreciation for how quickly team protocols were
adjusted to keep participants safe at the start of the
COVID-19 pandemic. Screening brought opportunities to link individuals who tested positive to care and
vaccinate individuals who tested negative. For example,
one community member remarked, “Screening more
patients, obviously finding those positives and then I
guess for the people that tested negative but who are
not immune, then they can get a chance of getting vaccinated and protecting themselves. So those are the things
that we were able to accomplish.” Especially for minorities without insurance, this project was important in
increasing the overall HBV vaccination rate. One member from a government organization stated, “We also
help to improve access to hepatitis B vaccination. We can
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provide hepatitis B vaccination for adults who are uninsured. And this is a critical population, especially among
immigrants new to the country, [who] don’t have insurance yet.” One of the community partnership members
further elaborated on how hepatitis prevention is not a
priority to the immigrant population: “They have a lot
of priority to deal with. So prevention care is definitely
not in priority.” Thus, the ACG partnership is taking a
big step forward in preventing hepatitis in the immigrant
population.
In terms of the partnership, members expressed that the
organizations have worked well together by having everyone at the table share, communicate strategies, build
capacity, and engage the community. One participant
from a government organization emphasized that these
types of partnerships can help build future partnerships
and collaboration among different organizations working
toward a common goal. One partnership member mentioned how obtaining funding was particularly successful
in the past year. Another government member discussed
how sharing project updates and strategies to overcome
barriers was especially helpful:
They give progress reports, they disclose challenges to
implementation. I remember, the last one, we talked
a lot about our COVID as it impacted the community outreach, testing, and ways that they can go
around the outcome, we continue to make sure that
we’re providing services, even amid COVID intervention, I think this is really very good.
Future goals for screening Partnership member goals
included meeting set numbers for screening, increasing education and vaccination, having sustainability of
screening and vaccination, involving “champions in the
community,” addressing HBV birth dose, working with
community organizations such as churches, educating the community about COVID-19 as partners adjust
to best accommodate patients, and raising awareness
about the hybrid model so members can register online
to get tested. For example, a community member shared,
“I mean, just maybe raise more awareness and let people know that [we have] that hybrid screening model so
that, you know, if they’re uncomfortable coming up to a
group setting, they can always register online or let them
let other people know about our online registration to get
tested.” Another participant hoped for a health fair to increase
the number of people screened and vaccinated for HBV.
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Future goals and recommendations for the ACG Partnership Goals for the ACG partnership include raising awareness about the high prevalence of HBV among
Asian and African immigrants and receiving continued
funding from government entities. Two members from
community and government organizations (respectively)
shared:
I think, more importantly, is rais [ing] awareness
with the government agency that’s providing the
funding to make sure that funding continues because
of the important work that’s being done in the unmet
needs that’s happening in viral hepatitis world, especially with hepatitis B. So I think, you know, in that
coalition meeting, what needs to be addressed is the
understanding that this is still an ongoing disease
burden that needs attention... and making sure that,
you know, there, there is a sustainable plan, in terms
of helping patients realize what the disease burden
is, and to raise awareness for prevention.
There might be an opportunity [to] enhance support
or funding for hepatitis B. That, I think, would be
necessary. And it’s only just now happening for hepatitis C. And this is very recent. I think hepatitis B
needs to be looked at similarly.
Other objectives include providing continuity of care for
individuals who test HBV positive, strengthening reporting systems and health information exchanges using electronic medical records (EMRs), and addressing HBV as
standardized screening. One community member shared:
That’s an important goal, having the EMR systems
that are able to do that are fundamental to that
process, because it helps clinicians, as they log on,
to always be reminded that HBV is part of routine
patient care. So that in Year 2 and Year 3, I hope
that there’s work to strengthen the EMR component,
as well as the health information exchange component, so that both the internal work around HBV
and the internal to external reporting and management are both strengthened.
Project challenges and barriers

Overall challenges to‑date Members revealed that coordinating project meeting times has been the biggest challenge, especially for those not working full-time. As one
community member shared:
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I think one of the biggest challenges of having
standing meetings is the time commitment, especially
if you’re asking individuals who are not doing this
as a full-time job to carve out some time during the
work week to meet, I think that could be potentially
one of the biggest challenges if this is not their
full-time job.
Contrary to their colleagues in the partnership, community members heavily emphasized “how [their] membership on the WB-HBV Project Task Force required/s a
considerable time commitment.” Attendance at meetings
by community members (1–3 meetings) was considerably lower than attendance by academics (7–9 meetings).
Some participants cited “busyness”, “being overly committed with other responsibilities”, and “low staff coverage to attend partnership meetings” as possible reasons.
As our project standing meetings were originally agreed
upon when the partnership initially formed, pre-covid,
it is very likely that new/additional responsibilities naturally arose over time due to the competing/
immediate priorities caused by the pandemic (especially for our community partners who were active
“in the field”).
In terms of communication between partners, members initially were not made aware of the expectations
and did not clearly understand project goals and outcomes. However, once information was shared with
them, they had a better grasp on their involvement and
contribution to the partnership. For example, one community member revealed:
In the beginning, we were having trouble kind of just
gathering all our information because everything
just started so we didn’t really know what information was expected from our organization, like
number-wise and stuff like that. But once we kind of
understood what was expected [it] was easier.
For HBV-related activities (screening, linkage to care,
and vaccination), some of the overall challenges mentioned included contacting the target population (including local organizations that serve racial/ethnic minority
communities), linking them to care, and working with
different communities in the WBMA area. A community member described mistrust as a challenge in HBVrelated activities because community organizations are
viewed differently from hospitals:
When they come, and of course, we have our banner, our website, and what we offer, but to them, it’s
still, “You’re not a hospital. So why should we go
there and get our blood drawn [ … ] from someone
we don’t know?”
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Anticipated future challenges and barriers and recommendations to overcome challenges Several anticipated
challenges were presented by partnership members. One
of the biggest challenges was associated with COVID19, which affected in-person interactions, and therefore
limited screening events, community health fairs, and
patients’ access to care. A community member shared,
“So they’re still not comfortable and that is kind of still a
challenge because every year we used to have, like, really
big health fairs whereby we are present in person, you
know. Anything that you do online is very different from
what you have in person.” Members also anticipated challenges to reaching other racial/ethnic minorities communities, such as the Latino or Hispanic populations.
Although they have identified these as priority populations, the partnership has not yet established relationships with organizations that predominantly serve these
populations. One community member said, “So that was
the part that’s new to us, the Hispanic community. We’ve
never been able to get into that community. [ …] So that’s
what we need, to get into that community more. So I
think that’s our barrier.”
Since HBV is incurable and requires prevention
resources, challenges within the ACG partnership may
include a lack of funding for screening and education or
overall funding for HBV-related activities. One member
from a government organization stated:
For example, there might be an opportunity to
enhance support for funding for hepatitis B. That,
I think, would be necessary. And it’s only just now
happening for hepatitis C. And this is very recent.
I think hepatitis B needs to be looked at similarly.
It’s always included, but it’s never received the right
attention because it’s not curable.
Another community member mentioned that using
evaluation to inform programming, sustain HBV-related
activities or programs, and build capacity around health
information exchanges or EMRs will be important
future work of the ACG partnership that will allow for “a
stronger linkage between the community, the community
partners and the health department around data.” Members also emphasized that important factors for the ACG
partnership are clear communication and transparent
goals and outcomes, equitable relationships with partners, and commitment of time.
Partnership’s involvement in government or policy

Current involvement in government or policy Overall,
partnership members indicated that more work should
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be done to increase HBV funding. One community member shared:
I think there should be more work done with state
legislators as well as state viral hepatitis coordinators. But it all really comes down to the federal government and whether or not there’s the budget allocated to address hepatitis B in particular, because I
know there is already funding for hepatitis C.
Future recommendations for involvement in government
or policy Partnership members felt that future efforts
should include increasing education and HBV vaccine
availability and addressing vaccine hesitancy. A community member noted that testing should be widely available to minority populations through similar projects:
Yes, my recommendation is to continue to increase
the number of testing, having testing available to
help the minority population to get to the point
of care. So, if they can have more testing and more
partnerships in [the] community that will be a good
thing. [Especially] if the work that is being done now
is [replicated] to have more people and more partners so that while we are targeting one community,
other communities [are] being targeted somewhere
else.
In addition, several members emphasized the importance
of disseminating findings of the project to legislatures
interested in immigrant health, which has been successfully done in the past. One member from the academic
organization stated, “I think one thing would be having
speakers come in, having us do a presentation with the
legislator … and I think when we talk about the dissemination of the findings, making sure we disseminate our
findings back to legislators, as they are key stakeholders.”

Discussion
This study provides insight into the facilitators and challenges of ACG partnerships and the importance of conducting partnership evaluations to improve partnership
function. The process evaluation of the WB-HBV Demonstration Project highlights the strengths of an ACG
partnership in addressing HBV disparities among racial/
ethnic minorities and at-risk communities [16]. Most
notably, during their first year, the partnership was able
to reach its goal of screening 2300 persons by screening
2495 persons, and provided 408 vaccine doses, of its projected goal of 400 doses. Overall, ACG members highlighted the partnership’s positive impact at informing
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HBV-related policy, reaching project goals and objectives, and overcoming barriers with innovative solutions
during the COVID-19 pandemic. Partnership members
also described challenges and areas to improve including communicating clear goals and outcomes, task force
meetings that are attended by everyone, and overcoming COVID-19-related difficulties in reaching the target
population.
Different organizations provided a variety of feedback
related to participation: community organization members felt more strongly that they had a positive impact
on the partnership, expressed a strong desire to contribute more in the allocation of resources, and described
the time required to participate as a major challenge;
academic members attended far more meetings (seven
to nine versus one to three for other members), felt the
most satisfied with their participation, but were more
varied on the clarity of the partnership’s vision; government members were the most positive about the partnership’s clear vision and following its own principles, and
(with communities members) were least positive about
the policy-impacting materials created as a result of the
partnership. These variations suggest that members of
different organizations have different experiences in, and
expectations for, the ACG partnership and introduce the
question of how best to structure partnerships so they
are more equitable for the members.
The existing literature from recent process evaluations
of CBPR partnerships validates (a) the value of the CBPR
process for improved outcomes; (b) the importance of
community members being involved at every stage of the
process; (c) the importance of relationship- and trustbuilding with community organizations; and (d) the
importance of the community to take ownership of the
project [17–23]. The literature also highlights the challenges of communication, inclusiveness, and community
involvement to successful CBPR [17–25].
CBPR, which necessitates an active partnership
of equal commitment among various organizations
throughout the entire research process, is essential in
addressing health disparities such as HBV among racial/
ethnic minority populations [26]. CBPR has been long
implemented in other communities such as the highly
noted Detroit Community-Academic Urban Research
Center’s Neighborhoods Working in Partnership (NWP)
[1]. In this current study, partners contributed their own
expertise and worked together to improve the lives of
community members living daily with HBV [1]. Similarly,
for this current partnership, all members of the project
team were involved in the process evaluation, which
was a method used to assess the process, impact, and
effectiveness of the WB-HBV Project. Findings strongly
highlighted the importance for partners to clearly (1)
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communicate and delineate the value of the partnership and meeting structure and (2) convey the important
role and contributions that community participants play
and provide. It is especially critical, at the early stages,
for ACG partnerships to create shared visions, norms,
and equitable leadership roles for all agencies/organizations involved [27]. This helps to create buy-in to the
collaboration and the partnership, and also motivation
to contribute in terms of time and commitment including attending meetings. Often it is the academic partners
doing the scheduling and attention needs to be given
allowing the community members to do the scheduling
of events and meeting with assistance from the academic
partners for equitability [27, 28]. Commitment and
investment of time can further be established by creating
bi-directional pathways of learning; it is just as important
that the ACG partnership that sets this also has a priority
to elicit investments of time, attention, and attendance to
the partnership [29].
The outcomes of our process evaluation comparably
reflect those as described in Israel et al. (2010) [1], and
were used to inform future CBPR efforts needed in DC
communities to enhance capacity building and advocate policy changes. A previous process evaluation of
CBPR in addressing HBV disparities highlighted that
ongoing process evaluations are necessary to assess
various partners’ current work, goals, and objectives
and, ultimately, to achieve stronger cohesion in reaching partnership goals [30]. Specifically, there are several
strategies and techniques that can increase the likelihood of partnership success [31–35]. As identified by
Israel and colleagues [15, 23, 31], these should include
(1) the facilitation of collaborative partnerships in all
phases of the research, (2) the integration of knowledge
and action for mutual benefit of all partners, and (3)
the promotion a co-learning and empowering process
that attends to social inequalities. Recognition of and
responsiveness to group dynamics [31, 34, 35], including the shared development of clear and operational
group goals that emphasize cooperation but reflect
individual interests, contributes to the effectiveness of a
diverse collaborating group, as does a climate that supports group cohesion [31–34]. In order for agreeable
project aims and outcome expectations to be shared by
partnership members, specific activities such as determining goals and prioritizing tasks based on theoretical
frameworks [23], adopting a centralized communication network where a few members receive and share
information [31], and encouraging small-group work
within each organization to identify any issues and/
or to regularly solicit ideas [31] are also necessary to
allow for members to have a sense of group belonging
and project accountability through team connectivity.

Page 18 of 20

Processes that facilitate equitably-distributed participation, open communication, and leadership that attends
to both relationship maintenance and tasks goals are
critical to the building and sustainment of effective
CBPR partnerships to achieve health equity [31–35].
Limitations

The data presented here reflect self-reported responses
belonging to a small and purposive sample of active
partnership members on the WB-HBV Project Task
Force. Results may have been subjected to respondent
and recall bias and are not generalizable. Nonetheless,
they do provide recommendations to strengthen and
structure similar ACG partnerships. Moreover, results
can be compared to other partnerships that used this
same survey [8]. However, the mixed-method study captured additional information that may have been missed
quantitatively.

Conclusions
This mixed-methods process evaluation on an ACG
partnership offers critically important insights into
developing strategies to enhance partnership functioning and increase the ability of this and future ACG
partnerships to improve community health outcomes.
The current process evaluation through a quantitative lens showed a general agreement among the three
organizations across a variety of the measures adopted
from Israel and colleagues, and the qualitative method
allowed members to voice detailed comments regarding meeting the ultimate goal of eliminating HBV
disparities in the WBMA. The results of the current
process evaluation reveal strengths and weaknesses
that may help to strengthen other ACG partnerships in
the future.
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